Switching to Angiotensin Receptor-Neprilysin Inhibitor and Reduced Risk of New-Onset Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction: A Nationwide Propensity Score-Matched Study

Eur Heart J Cardiovasc Pharmacother. 2026 Sep 15:pvag074. doi: 10.1093/ehjcvp/pvag074. Online ahead of print.ABSTRACTAIMS: We investigated whether switching from traditional renin-angiotensin system (RAS) blockade to angiotensin receptor-neprilysin inhibitor (ARNI) is associated with a lower risk of

Y Young Jun Park

Microbiome and atherosclerosis: hype or future therapeutic target?

J Basic Clin Physiol Pharmacol. 2026 Sep 16. doi: 10.1515/jbcpp-2025-0190. Online ahead of print.ABSTRACTFrom 2010 to 2025, evidence increasingly identifies the gut microbiome, microbial dysbiosis, trimethylamine-N-oxide (TMAO), and short-chain fatty acids (SCFAs) as modulators of atherosclerosis an

Z Zoya Hussain

Contraceptive Counseling and Options in Patients With Cardiovascular Disease

Clin Obstet Gynecol. 2026 Sep 15. doi: 10.1097/GRF.0000000000001057. Online ahead of print.ABSTRACTCardiovascular disease is among the leading causes of maternal morbidity and mortality in the United States. In patients with underlying cardiovascular disease, safe and effective contraception can pre

E Eleanor Christenson

Cardiovascular Risks in Autoimmune and Inflammatory Diseases

J Clin Med. 2026 Sep 7;15(17):6914. doi: 10.3390/jcm15176914.ABSTRACTAutoimmune and inflammatory diseases are characterized by complex pathophysiological mechanisms that promote systemic inflammation and multi-organ involvement [...].PMID:42739915 | DOI:10.3390/jcm15176914

E Elena Rezus